share_log

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K: Report of foreign private issuer [Rules 13a-16 and 15d-16]

Redhill Biopharma | 6-K：外国发行人报告
美股sec公告 ·  04/24 07:08
Moomoo AI 已提取核心信息
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced the enrollment of the first patient in the ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment. The trial is evaluating RHB-107 (upamostat), a novel oral antiviral, and is supported by the U.S. Department of Defense among other non-dilutive external sources. The study, which is expected to conclude by the end of 2024, is being conducted across multiple countries including the U.S., Thailand, Ivory Coast, South Africa, and Uganda. RHB-107 has previously shown promising results in a U.S. Phase 2 study, with a significant reduction in COVID-19 hospitalizations and new severe symptoms. The drug is host-directed and is expected to be effective against viral variants due to...Show More
RedHill Biopharma Ltd., a specialty biopharmaceutical company, has announced the enrollment of the first patient in the ACESO PROTECT multinational platform trial for early COVID-19 outpatient treatment. The trial is evaluating RHB-107 (upamostat), a novel oral antiviral, and is supported by the U.S. Department of Defense among other non-dilutive external sources. The study, which is expected to conclude by the end of 2024, is being conducted across multiple countries including the U.S., Thailand, Ivory Coast, South Africa, and Uganda. RHB-107 has previously shown promising results in a U.S. Phase 2 study, with a significant reduction in COVID-19 hospitalizations and new severe symptoms. The drug is host-directed and is expected to be effective against viral variants due to its mechanism of action. RedHill's COO, Gilead Raday, highlighted the potential of RHB-107 to provide an additional treatment option for early COVID-19 alongside existing treatments like Paxlovid. The company is also progressing with opaganib, another oral drug, for pandemic preparedness, including Acute Radiation Syndrome, in collaboration with the U.S. National Institutes of Health.
专业生物制药公司RedHill Biopharma Ltd. 宣布ACESO PROTECT跨国平台试验招募首位患者进行早期 COVID-19 门诊治疗。该试验正在评估一种新型口服抗病毒药物 RHB-107（upamostat），并得到了美国国防部以及其他非稀释性外部来源的支持。该研究预计将于2024年底结束，正在包括美国、泰国、科特迪瓦、南非和乌干达在内的多个国家进行。RHB-107 此前在美国一项二期研究中显示出令人鼓舞的结果，COVID-19 住院人数显著减少，出现了新的严重症状。该药物以宿主为导向，由于其作用机制，有望对病毒变异有效。RedHill 的首席运营官吉利德·雷迪强调，除了 Paxlovid 等现有疗法，RHB-107 有可能为早期 COVID-19 提供额外的治疗选择。该公司还与美国国立卫生研究院合作开发另一种口服药物奥帕加尼布，用于防备疫情，包括急性辐射综合症。
专业生物制药公司RedHill Biopharma Ltd. 宣布ACESO PROTECT跨国平台试验招募首位患者进行早期 COVID-19 门诊治疗。该试验正在评估一种新型口服抗病毒药物 RHB-107（upamostat），并得到了美国国防部以及其他非稀释性外部来源的支持。该研究预计将于2024年底结束，正在包括美国、泰国、科特迪瓦、南非和乌干达在内的多个国家进行。RHB-107 此前在美国一项二期研究中显示出令人鼓舞的结果，COVID-19 住院人数显著减少，出现了新的严重症状。该药物以宿主为导向，由于其作用机制，有望对病毒变异有效。RedHill 的首席运营官吉利德·雷迪强调，除了 Paxlovid 等现有疗法，RHB-107 有可能为早期 COVID-19 提供额外的治疗选择。该公司还与美国国立卫生研究院合作开发另一种口服药物奥帕加尼布，用于防备疫情，包括急性辐射综合症。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息